

CORRECTED VERSION

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
24 September 2009 (24.09.2009)

PCT

(10) International Publication Number  
WO 2009/117080 A8

## (51) International Patent Classification:

C07D 239/88 (2006.01) A61K 31/517 (2006.01)  
C07D 239/93 (2006.01) A61P 35/00 (2006.01)

## (21) International Application Number:

PCT/US2009/001659

## (22) International Filing Date:

17 March 2009 (17.03.2009)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

61/069,763 17 March 2008 (17.03.2008) US  
61/110,508 31 October 2008 (31.10.2008) US(71) Applicant (for all designated States except US): AMBIT  
BIOSCIENCES CORPORATION [US/US]; 4215 Sorrento Valley Boulevard, San Diego, CA 92121 (US).

## (72) Inventors; and

(75) Inventors/Applicants (for US only): ABRAHAM, Sunny [IN/US]; 4215 Sorrento Valley Boulevard, San Diego, CA 92121 (US). BHAGWAT, Shripad, S. [US/US]; 4215 Sorrento Valley Boulevard, San Diego, CA 92121 (US). CAMPBELL, Brian, T. [US/US]; 4215 Sorrento Valley Boulevard, San Diego, CA 92121 (US). CHAO, Qi [US/US]; 4215 Sorrento Valley Boulevard, San Diego, CA 92121 (US). FARAONI, Raffaella [IT/US]; 4215 Sorrento Valley Boulevard, San Diego, CA 92121 (US). HOLLADAY, Mark, W. [US/US]; 4215 Sorrento Valley Boulevard, San Diego, CA 92121 (US). LAI, Andilly, G. [US/US]; 4215 Sorrento Valley Boulevard, San Diego, CA 92121 (US). ROWBOTTOM, Martin, W. [GB/US]; 4215 Sorrento Valley Boulevard, San Diego, CA 92121 (US). SETTI, Eduardo [AR/US]; 4215 Sorrento Valley Boulevard, San Diego, CA 92121 (US). SPRANKLE,

Kelly, G. [US/US]; 4215 Sorrento Valley Boulevard, San Diego, CA 92121 (US).

(74) Agents: INSOGNA, Anthony, M. et al.; Jones Day, 222 East 41st Street, New York, NY 10017-6702 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Published:

— with international search report (Art. 21(3))


## (48) Date of publication of this corrected version:

4 November 2010

## (15) Information about Correction:

see Notice of 4 November 2010

(54) Title: QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF



I

(57) Abstract: Compounds according to formula (I), compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases. Formula (I): or a pharmaceutically acceptable salt, solvate, clathrate of hydrate thereof, wherein X is O or S(O); R<sup>a</sup> is O or S.